Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT03116113
XIRIUS
A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR).
Type: Interventional
Status of the trial: Completed
Orphan Drug Recognition: No
Inclusion
- Opening Date: 2017-08-01
- Closing Date: 2018-01-31
Criteria
Children: Yes
Adults: Yes
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Principal investigators
Other investigators
Workgroups
Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
